MLTX compared with OCUL: revenue, margins and what each company keeps, and the suppliers and customers both name

MLTXMoonLake Immunotherapeutics

Mkt capRevenueRevenue

OCULOcular Therapeutix, Inc

Mkt capRevenueRevenue

Compare

MLTXMoonLake Immunotherapeutics

OCULOcular Therapeutix, Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

MLTX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±23.0%▼−5.09%×0.22

OCUL

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.6%▲+2.82%×0.21

Q1 FY26±8.0%▼−0.61%×0.07

= impliedMLTX realized, solidOCUL realized, hatchedOne scale, both sides: full bar = 51%× = |realized| ÷ impliedSource: market data

Feb 5 '26

±50.7%

▲+4.21%

×0.08

Nov 4 '25±10.3%▼−4.47%×0.44

MLTXMoonLake Immunotherapeutics

11.47· pre 11.53· delayed

Mkt cap$1.0BRevenue—Revenue—

OCULOcular Therapeutix, Inc

6.73· pre 6.93· delayed

Pre-marketNov 3 '26delayed

Mkt cap$1.5BRevenue$13MQ2 FY26Revenue$52MFY25

Compare

Pre-marketNov 3 '26delayed

MLTXMoonLake Immunotherapeutics

OCULOcular Therapeutix, Inc

11.47pre 11.53delayed

Price

6.73pre 6.93delayed

$1.0B

Mkt cap

$1.5B

—

Revenue

$13MQ2 FY26

—

Revenue

$52MFY25

MLTX11.47vsOCUL6.73Pre-marketNov 3 '26delayed